epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

BMJ

Pregabalin misuse declines after safety crackdown

November 17, 2026

card-image

Clinical takeaway: Reassess ongoing pregabalin therapy regularly, especially in patients receiving opioids or benzodiazepines concurrently. Regulatory warnings and closer monitoring may help reduce misuse and overdose, but high-risk use remains common and warrants continued vigilance.

Pregabalin prescribing has risen sharply worldwide alongside concerns about misuse, dependence, and overdose. Australia is one of the first countries to report a sustained reversal of that trend after a series of regulatory actions and high-profile media reports highlighting pregabalin-related harms.

After years of growth, pregabalin use in Australia peaked in 2018 and then began to plateau and decline. Investigators identified three major turning points: widespread media coverage of pregabalin harms in late 2018, tighter prescribing and dispensing restrictions in 2020, and boxed safety warnings introduced in 2021.

Compared with projected historical trends, pregabalin dispensing was 25% lower than expected after the interventions, equivalent to about 118,000 fewer prescriptions nationally in December 2021. Dispensing continued to decline afterward at roughly 0.7% per month.

Pregabalin overdose calls also fell. Relative to projected trends, overdose rates were 47% lower, corresponding to an estimated 41 fewer monthly overdose calls to Australia's largest poison center by December 2021, with an ongoing monthly decline of 1.6%.

High-risk use remained common. Among nearly 58,000 pregabalin users evaluated after the final intervention, 13.5% were classified as high risk based on factors such as high doses, early refills, multiple prescribers, and concurrent sedative use. Within this group, 66% received opioids and 32% received benzodiazepines.

The investigators analyzed national prescription claims and poison-center data from 2016 through 2024. Primary outcomes were population-adjusted rates of pregabalin dispensing and intentional overdose, including misuse, recreational use, and self-harm exposures.

The findings suggest that multifaceted interventions, including risk communication, prescribing restrictions, boxed warnings, and prescription-monitoring programs, may help curb pregabalin-related harms. However, nearly half of pregabalin users still received concurrent opioid therapy, indicating substantial room for improvement in safer prescribing practices.

In a linked editorial, David Juurlink, a clinical pharmacologist and drug safety researcher at the University of Toronto, urged clinicians to use pregabalin more selectively and only when patients derive meaningful benefit. He specifically cautioned against viewing the drug as a routine analgesic for conditions such as low back pain or sciatica.

“Persisting with ineffective treatment or escalating the dose in pursuit of relief that has yet to materialise is more than misplaced optimism. It is an invitation to harm,” wrote Juurlink.

Source: Cairns R, et al. (2026 Nov 11) BMJ. Changes in pregabalin use and overdose after government interventions and media coverage: retrospective observational study

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information